GeoVax has strengthened its Gedeptin therapy platform with newly allowed patent claims covering the synergistic combination of gene therapy with radiation for treating various solid tumors.
GeoVax's next-generation COVID-19 vaccine GEO-CM04S1 continues clinical development for immunocompromised populations, with key data readouts expected in Q2 2025 despite recent BARDA funding termination.
GeoVax is focusing on advancing its Phase 2 clinical-stage products, Gedeptin for head and neck cancer, and GEO-CM04S1, a next-generation COVID-19 vaccine.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.